Sanofi to buy back Genzyme-linked CVRs for $70 mln
PARIS, Oct 8 (Reuters) - French drugmaker Sanofi said on Monday it will buy back certificates related to the success of Genzyme drugs for a total cost of about $70 million, representing $1.75 per contingent value right (CVR).
Sanofi said last month it would buy back up to $152 million worth of the outstanding CVRs , which are linked to its 2011 purchase of U.S. biotech Genzyme. It said then it would pay between $1.50 and $1.75 per CVR.
(Editing by Christian Plumb)
((james.regan@thomsonreuters.com)(+33)(0)(1 49 49 53 84)(Reuters Messaging: james.regan.thomsonreuters.com@reuters.net))
Keywords: SANOFI GENZYME/
PARIS, Oct 8- French drugmaker Sanofi said on Monday it will buy back certificates related to the success of Genzyme drugs for a total cost of about $70 million, representing $1.75 per contingent value right. Sanofi said last month it would buy back up to $152 million worth of the outstanding CVRs, which are linked to its 2011 purchase of U.S. biotech Genzyme.